BenzingaSeptember 3, 2026 at 9:32 AM NYyesterday
Piper Sandler Reiterates Overweight on Biogen, Raises Price Target to $245
Piper Sandler analyst David Amsellem reiterates Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $225 to $245.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga
Companies in This Story
Related Stories
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
Yahoo4 hours ago
Exploring the top movers within the S&P500 index during today's session.
ChartMill50 minutes ago
Sector Update: Financial
Yahoo2 hours ago
Will Fiserv’s (FISV) Cut 2026 Outlook and Margin Pressures Change Its Transformation Narrative?
Yahoo2 hours ago
The trading volume of these stocks is deviating from the norm in today's session.
ChartMill2 hours ago